Dual targeting of retinal vasculature in the mouse model of oxygen induced retinopathy

Open Diabetes Journal

Volumn 4, Issue SPEC. ISSUE 1, 2011, Pages 60-74

  DeNiro, Michael ^a,b   Al Mohanna, Futwan ^b  

^a KING KHALED EYE SPECIALIST HOSPITAL   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Angiogenesis; HIF 1; OIR; Retinal vasculature; Targeting; YC 1

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ENDOTHELIN 1; ERYTHROPOIETIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1; INDUCIBLE NITRIC OXIDE SYNTHASE; LIFICIGUAT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SMALL INTERFERING RNA; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HYPOXIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RETINA BLOOD VESSEL; RETINA NEOVASCULARIZATION; RETINOPATHY; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 80455174137     PISSN: None     EISSN: 18765246     Source Type: Journal    
DOI: 10.2174/1876524601104010060     Document Type: Review

References (101)

1. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
2. Gargett CE RP. Human endometrial angiogenesis. Reproduction 2001; 121: 181-6.
3. Egginton S HO, Brown MD, Walter H, Weiss JB, Bate A. Capillary growth in relation to blood flow and performance in overloaded rat skeletal muscle. J Appl Physiol 1998; 85: 2025-32.
4. Kerbel R. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000; 21: 505-15.
5. Breier G DA, Plate KH, Risau W. Angiogenesis in embryos and ischemic diseases. Thromb Haemost 1997; 78: 678-83.
6. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
7. Ware JA SM. Angiogenesis in ischemic heart disease. Nat Med 1997; 3: 158-64.
8. Isner J. Manipulating angiogenesis against vascular disease. Hosp Pract (Minneap) 1999; 34: 69-74, 6, 9-80 passim.
9. Baffour R BJ, Garb JL, Rhee SW, Kaufman J, Friedmann P. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. J Vasc Surg 1992; 16: 181-91.
10. Shweiki D IA, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-5.
11. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-95.
12. Michaelson I. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK 1948; 68: 137-80.
13. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 1: 4-25.
14. Klagsbrun M, D'Amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996; 3: 259-70.
15. Murata T, Ishibashi T, Khalil A, Hata Y, Yoshikawa H, Inomata H. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res 1995; 27: 48-52.
16. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001; 10: 2408-13.
17. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 6: 961-9.
18. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003; 44: 2155-62.
19. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 6: 653-60.
20. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 6801: 249-57.
21. Gariano RF, Gardner TW. Retinal angiogenesis in development and disease. Nature 438: 960-6.
22. Otani A KK, Ewalt K, Otero FJ, et al. Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat Med 2002; 8: 1004-10.
23. Gardner TW, Antonetti DA. A prize catch for diabetic retinopathy. Nat Med 2007; 2:131-2.
24. Saint-Geniez M DAP. Development and pathology of the hyaloid, choroidal and retinal vasculature. Int J Dev Biol 2004; 48: 1045-58.
25. Lu X LNF, Yuan L, Jiang Q, et al. The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Eichmann Nature 2004; 432: 179-86.
26. Uemura AOM, Hirashima M, Fujiwara T, et al. Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest 2002; 110: 1619-28.
27. Gerhardt H GM, Fruttiger M, Ruhrberg C, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003; 161:1163-77.
28. Aiello L. Angiogenic pathways in diabetic retinopathy. N Engl J Med 2005; 353: 839-41.
29. Ambati J AA, Fernandez S, Sakurai E, et al. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med 2003; 9: 1390-7.
30. Dewan ALM, Hartman S, Zhang SS, et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 2006; 314: 989-92.
31. Sheth JJ. Diabetes, microalbuminuria and hypertension. Clin Exp Hypertens 1999; 21: 61-8.
32. Russ PK, Gaylord GM, Haselton FR. Retinal vascular permeability determined by dual-tracer fluorescence angiography. Ann Biomed Eng 2001; 29: 638-47.
33. Barinaga, M. Shedding light on blindness. Science 1995; 267: 452-3.
34. Williamson JR, Chang K, Frangos M. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42: 801-13.
35. Shiels IA, Zhang S, Ambler J, Taylor SM. Vascular leakage stimulates phenotype alteration in ocular cells, contributing to the pathology of proliferative vitreoretinopathy. Med Hypotheses 1998; 50: 113-7.
36. Stitt AW, Bhaduri T, McMullen CB, Gardiner TA, Archer DB. Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol Cell Biol Res Commun 2000; 3: 380-8.
37. Ashton N. Retinal vascularization in health and disease. Am J Ophthalmol 1957; 44: 7-17.
38. Campochiaro PA. Retinal and choroidal neovascularization. J Cell Physiol 2000; 184: 301-310.
39. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci 2003; 28: 488-94.
40. Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE 2001; 112 (RE21): 1-17.
41. Thieme H, Aiello LP, Takagi H, Ferrara N, King GL. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes 1995; 44: 98-103.
42. Pe'er J FR, Itin A, Gnessin H, Hemo I, Keshet E. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol 1996; 80: 241-5.
43. Amin RH FR, Kennedy A, Eliott D, Puklin JE, Abrams GW. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1997; 38: 36-47.
44. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-50.
45. Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1519-20.
46. Fruttiger M. Development of the mouse retinal vasculature: angiogenesis versus vasculogenesis. Invest Ophthalmol Vis Sci 2002; 43: 522-7.
47. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995; 1: 1024-8.
48. Grant MBMW, Caballero S, Brown GA, et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med 2002; 8: 607-12.
49. Ishida S YK, Usui T, Kaji Y, Ogura Y, et al. Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat Med 2003; 9: 781-8.
50. Alvarez Y CM, Cottell DC, Bill BR, et al. Genetic determinants of hyaloid and retinal vasculature in zebrafish. BMC Dev Biol 2007; 7: 114.
51. Chan-Ling T GB, Stone J. The effect of oxygen on vasoformative cell division. Evidence that 'physiological hypoxia' is the stimulus for normal retinal vasculogenesis. Invest Ophthalmol Vis Sci 1995; 36: 1201-14.
52. Criscuoli ML NM, Eliceiri BP. Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. Blood 105:1508-1514. (VEGF) expression by neuroglia. J Neurosci 2005; 15: 4738-47.
53. Björndahl MA CR, Burton JB, Brakenhielm E, et al. Vascular endothelial growth factor-A promotes peritumoral lymphangiogenesis and lymphatic metastasis. Cancer Res 2005; 65: 9261-8.
54. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-6.
55. Czyzyk-Krzeska MF, Paulding WR, Beresh JE, Kroll SL. Post-transcriptional regulation of tyrosine hydroxylase gene expression by oxygen in PC12 cells. Kidney Int 1997; 2: 585-90.
56. Bunn HF, Poyton RO. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 1996; 3: 839-885.
57. Wenger RH. Mammalian oxygen sensing, signaling and gene regulation. J Exp Biol 2000; 203: 1253-63.
58. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 2005; 72: 638-45.
59. Wang GL, Semenza G. Molecular basis of hypoxia-induced erythropoietin expression. Curr Opin Hematol 1996; 3: 156-62.
60. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 6: 5510-4.
61. Chilov D, Camenisch G, Kvietikova I, Ziegler U, Gassmann M, Wenger RH. Induction and nuclear translocation of hypoxia-inducible factor-1 (HIF-1): heterodimerization with ARNT is not necessary for nuclear accumulation of HIF-1a. J Cell Sci 1999; 112: 1203-12.
62. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996; 30: 17771-8.
63. Jiang BH AF, Passaniti A, Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 1997; 57: 5328-35.
64. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998; 14: 7987-92.
65. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 2001; 13: 167-71.
66. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294: 1337-40.
67. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 1: 43-54.
68. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468-472.
69. Masson N, Ratcliffe PJ. HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O(2) levels. J Cell Sci 2003; 15: 3041-9.
70. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, Gassmann M. Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J 2001; 15: 1312-4.
71. Jeong JW, Bae MK, Ahn MY, et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002; 5: 709-20.
72. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-13.
73. Melillo G MT, Sica A, Taylor LS, Cox GW, Varesio L. A hypoxia responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 1995; 6: 1683-93.
74. Jing Hu D, Discher Daryl J, Bishopric Nanette H, Webster Keith A. Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxiainducible factor-1 binding site on the antisense strand. Biochem Biophys Res Commun 1998; 245: 894-9.
75. Ozaki H, Yu AY, Della N, et al. Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 1999; 40: 182-9.
76. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1-alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997; 94: 4273-8.
77. Gu YZ, Moran SM, Hogenesch JB, Wartman L, Bradfield CA. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3 alpha. Gene Expr 1998; 7: 205-13.
78. Wiesener MS, Turley H, Allen WE, et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood 1998; 92: 2260-8.
79. Hara S, Hamada J, Kobayashi C, Kondo Y, Imura N. Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: suppression of HIF-mediated gene expression by HIF-3alpha. Biochem Biophys Res Commun 2001; 4: 808-13.
80. Minet E MD, Michel G, Roland I, et al. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett 1999; 460: 251-6.
81. Isaacs JS JY, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia inducible factor-1 alpha-degradative pathway. J Biol Chem 2002; 277: 29936-44.
82. Mabjeesh NJ PD, Willard MT, Kaur B, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002; 62: 2478-82.
83. Chen C PN, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 2001; 276: 9519-25.
84. Treins C G-PS, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. Biol Chem 2002; 277: 27975-81.
85. Zhong H CK, Feldser D, Laughner E, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/ AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60: 1541-5.
86. Fukuda R HK, Fan F, Jung YD, Ellis LM, Semenza GL. Insulinlike growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002; 277: 38205-11.
87. Stiehl DP JW, Wenger RH, Hellwig-Burgel T. Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett 2002; 512: 157-62.
88. Ko FN WC, Kuo SC, Lee FY, Teng CM. YC-1, a novel activator of platelet guanylate cyclase. Blood 1994; 84: 4226-33.
89. Teng CM, Wu CC, Ko FN, Lee FY, Kuo SC. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol 1997; 320: 161-6.
90. Hsieh GC ONA, Moreland RB, Sullivan JP, Brioni JD. YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats. Eur J Pharmacol 2003; 458: 183-9.
91. Friebe A KD. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol Pharmacol 1998; 53: 123-7.
92. Lee YC ME, Murad F. Human recombinant soluble guanylyl cyclase: expression, purification, and regulation. Proc Natl Acad Sci USA 2000; 97: 10763-8.
93. Chun YS YE, Choi E, Teng CM, Bae JM, Kim MS, Park JW. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 2001; 61: 947-54.
94. DeNiro M, Al-Mohanna FH, Al-Halafi A, Alsmadi O, Al-Mohanna F. Pleiotropic Effects of YC-1 Attenuates Pathological Retinal Neovascularization. Invest Ophthalmol Vis Sci 2009a; ARVO E-abstract# 41.
95. DeNiro M, Alsmadi O, Al-Mohanna F. Modulating the hypoxia-inducible factor signaling pathway as a therapeutic modality to regulate retinal angiogenesis. Exp Eye Res 2009b; 89: 700-17.
96. DeNiro M, Al-Halafi A, Al-Mohanna FH, Alsmadi O, Al-Mohanna FA. Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygen-induced retinopathy. Mol Pharmacol 2010; 3: 348-67.
97. Yun S LS, Kang YH, Jeong M, et al. YC-1 enhances natural killer cell differentiation from hematopoietic stem cells. Int Immunopharmacol 2010; 10: 481-6.
98. Mujoo K SV, Bryan NS, Krumenacker JS, et al. Role of nitric oxide signaling components in differentiation of embryonic stem cells into myocardial cells. Proc Natl Acad Sci USA 2008; 105:18924-9.
99. Pan W QL, Song LH, Yu YH, et al. Genistein stimulates the osteoblastic differentiation via NO/cGMP in bone marrow culture. J Cell Biochem 2005; 94: 307-16.
100. Tsai IF LC, Huang CT, Lin YC, Yang CM, Lin YC, Liao CH. Modulation of human monocyte-derived dendritic cells maturation by a soluble guanylate cyclase activator, YC-1, in a cyclic nucleotide independent manner. Int Immunopharmacol 2007; 7: 1299-310.
101. Xia XB XS, Xu HZ, Jiang J, Li Y. Suppression of retinal neovascularization by shRNA targeting HIF-1alpha. Curr Eye Res 2008; 10: 892-902.